Trial Profile

A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AADvac 1 (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Proof of concept
Acronyms ADAMANT
Sponsors Axon Neuroscience

Most Recent Events

30 Jul 2021 Results assessing mechanism of action and efficacy of AADvac1 in patients with mild alzheimers disease dementia, presented at the Alzheimer's Association International Conference 2021.
16 Jun 2021 Results presented in the Axon Neuroscience Media Release.
14 Jun 2021 Results presented in an Axon Neuroscience Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com